Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 1Phase 4 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Pancreatic Neoplasms 1Neoplasms 1Neoplasm Metastasis 1Hyperlipoproteinemia Type II 1Glioma 1Glioblastoma 1

Interventions

Cyclophosphamide 5Positron Emission Tomography Computed Tomography 4pembrolizumab 3Topotecan 2Surveys and Questionnaires 2Psilocybin 2Midazolam 2Methods 2Ketoconazole 2Ketamine 2temsirolimus 1posaconazole 1poly ICLC 1parathyroid hormone-related peptide (1-36) 1lavender oil 1jojoba wax 1ginger extract 1fluoromisonidazole 1fludarabine phosphate 1fludarabine 1fluciclovine F-18 1evolocumab 1etoposide phosphate 1beta-Glucans 1Whole-Body Irradiation 1Vincristine 1Varenicline 1Transplantation 1Transcranial Direct Current Stimulation 1Tetrahydrouridine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase EARLY_PHASE1 × Neoplasms × evolocumab × Clear all
NCT04862260 2026-03-19

Cholesterol Disruption in Combination With the Standard of Care in Patients With Advanced Pancreatic Adenocarcinoma

CHU de Quebec-Universite Laval

Phase EARLY_PHASE1 Active not recruiting
3 enrolled
Gastrointestinal

Hyperlipoproteinemia Type II, Neoplasm Metastasis, Neoplasms, Pancreatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡